CN102958540B - 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合 - Google Patents

含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合 Download PDF

Info

Publication number
CN102958540B
CN102958540B CN201180029827.XA CN201180029827A CN102958540B CN 102958540 B CN102958540 B CN 102958540B CN 201180029827 A CN201180029827 A CN 201180029827A CN 102958540 B CN102958540 B CN 102958540B
Authority
CN
China
Prior art keywords
alkyl
component
amino
combination
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180029827.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102958540A (zh
Inventor
刘宁姝
A.海格巴斯
K.海克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102958540(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN102958540A publication Critical patent/CN102958540A/zh
Application granted granted Critical
Publication of CN102958540B publication Critical patent/CN102958540B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN201180029827.XA 2010-04-16 2011-04-14 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合 Expired - Fee Related CN102958540B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10160109.4 2010-04-16
EP10160109 2010-04-16
PCT/EP2011/055917 WO2011128407A2 (en) 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Publications (2)

Publication Number Publication Date
CN102958540A CN102958540A (zh) 2013-03-06
CN102958540B true CN102958540B (zh) 2015-09-02

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180029827.XA Expired - Fee Related CN102958540B (zh) 2010-04-16 2011-04-14 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合

Country Status (24)

Country Link
US (1) US20130184270A1 (cg-RX-API-DMAC7.html)
EP (1) EP2558126A2 (cg-RX-API-DMAC7.html)
JP (1) JP5886271B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130098155A (cg-RX-API-DMAC7.html)
CN (1) CN102958540B (cg-RX-API-DMAC7.html)
AU (1) AU2011240003A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012026480A2 (cg-RX-API-DMAC7.html)
CA (1) CA2796253A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012002887A1 (cg-RX-API-DMAC7.html)
CO (1) CO6620036A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120524A (cg-RX-API-DMAC7.html)
CU (1) CU20120150A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000269A (cg-RX-API-DMAC7.html)
EA (1) EA201201414A8 (cg-RX-API-DMAC7.html)
EC (1) ECSP12012261A (cg-RX-API-DMAC7.html)
IL (1) IL222356A0 (cg-RX-API-DMAC7.html)
MA (1) MA34158B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012012064A (cg-RX-API-DMAC7.html)
PE (1) PE20130191A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012502069A1 (cg-RX-API-DMAC7.html)
SG (1) SG184550A1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000493A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011128407A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201208616B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
EA031493B9 (ru) 2013-04-08 2019-12-18 Байер Фарма Акциенгезельшафт Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
KR20180013851A (ko) * 2015-03-09 2018-02-07 바이엘 파마 악티엔게젤샤프트 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물
EA201791975A1 (ru) * 2015-03-09 2018-03-30 Байер Фарма Акциенгезельшафт ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ
WO2017153220A1 (en) * 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129246A2 (en) * 2008-04-14 2009-10-22 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US7511041B2 (en) * 2002-09-30 2009-03-31 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004037875B4 (de) 2004-08-04 2008-05-08 Siemens Ag Sensorvorrichtung, Verfahren und Vorrichtung zum Überwachen einer Sensorvorrichtung
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129246A2 (en) * 2008-04-14 2009-10-22 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-kinase Inhibitors in Basal-Like Breast Cancer Models;Klaus P. Hoeflich et al.;《Clinical Cancer Research》;20090715;第15卷(第14期);4649-4664 *

Also Published As

Publication number Publication date
CL2012002887A1 (es) 2013-01-18
PH12012502069A1 (en) 2013-02-04
MX2012012064A (es) 2012-12-17
TN2012000493A1 (en) 2014-04-01
CO6620036A2 (es) 2013-02-15
ZA201208616B (en) 2015-08-26
US20130184270A1 (en) 2013-07-18
EP2558126A2 (en) 2013-02-20
CU20120150A7 (es) 2013-02-26
EA201201414A1 (ru) 2013-04-30
WO2011128407A2 (en) 2011-10-20
CR20120524A (es) 2013-01-09
KR20130098155A (ko) 2013-09-04
SG184550A1 (en) 2012-11-29
WO2011128407A9 (en) 2011-12-22
JP5886271B2 (ja) 2016-03-16
WO2011128407A3 (en) 2012-02-23
JP2013525293A (ja) 2013-06-20
CA2796253A1 (en) 2011-10-20
IL222356A0 (en) 2012-12-31
HK1182937A1 (en) 2013-12-13
PE20130191A1 (es) 2013-02-21
MA34158B1 (fr) 2013-04-03
BR112012026480A2 (pt) 2016-08-16
ECSP12012261A (es) 2012-11-30
DOP2012000269A (es) 2012-12-15
AU2011240003A1 (en) 2012-11-08
EA201201414A8 (ru) 2013-12-30
CN102958540A (zh) 2013-03-06

Similar Documents

Publication Publication Date Title
CN102958540B (zh) 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合
JP5763834B2 (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン塩類
US9381177B2 (en) Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
JP2018512403A (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
JP7475402B2 (ja) 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用
HK1182937B (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
HK1187811A (en) Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
HK40015063A (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
NZ616198B2 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Liu Ningshu

Inventor after: A. Haigebasi

Inventor after: K. Hayek

Inventor before: Liu Ningshu

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: LIU NINGSHU TO: LIU NINGSHU A. HAEGEBARTH K. HAIKE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1182937

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1182937

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150902

Termination date: 20180414

CF01 Termination of patent right due to non-payment of annual fee